Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline

Ton Kuijpers,1 Frederick A Spencer,2 Reed A C Siemieniuk,3 4 Per O Vandvik,5 6 Catherine M Otto,7 Lyubov Lytvyn,2 Hassan Mir,2 Albert Y Jin,8 Veena Manja,9 Ganesan Karthikeyan,10 Elke Hoendermis,11 Janet Martin,12 Sebastian Carballo,13 Martin O’Donnell,14 Trond Vartdal,15 Christine Baxter,16 Bray Patrick-Lake,17 Joanie Scott,18 Thomas Agoritsas,3 19 Gordon Guyatt2 3

Options for the secondary prevention of stroke in patients younger than 60 years who have had a cryptogenic ischaemic stroke thought to be secondary to patent foramen ovale (PFO) include PFO closure (with antiplatelet therapy), antiplatelet therapy alone, or anticoagulants. International guidance and practice differ on which option is preferable.

The BMJ Rapid Recommendations panel used a linked systematic review1 triggered by three large randomised trials published in September 2017 that suggested PFO closure might reduce the risk of ischaemic stroke more than alternatives.2 4 The panel felt that the studies, when considered in the context of the full body of evidence, might change current clinical practice.1 The linked systematic review finds that PFO closure prevents recurrent stroke relative to antiplatelet therapy, but possibly not relative to anticoagulants, and is associated with procedural complications and persistent atrial fibrillation.1 The review also presents evidence regarding the role of anticoagulants or antiplatelet therapy when PFO closure is not acceptable or is contraindicated.

This expert panel make a
• Strong recommendation in favour of PFO closure plus antiplatelet therapy compared with antiplatelet therapy alone
• Weak recommendation in favour of PFO closure plus antiplatelet therapy compared with anticoagulants
• Weak recommendation in favour of anticoagulants compared with antiplatelet therapy.

The largest challenge in making our recommendation was the low quality evidence for the comparisons that included anticoagulants. We summarised all the high-quality available evidence separately for antiplatelet therapy and anticoagulants because the evidence suggests it is likely their effectiveness and adverse effects differ, and clinicians and patients should be aware of these likely differences. Our panel believes that the mechanism of benefit with PFO closure is prevention of venous clots crossing the PFO. Anticoagulants are likely to be substantially more effective in preventing such clots from initially arising than antiplatelet agents.

Box 1 shows the articles and linked evidence in this Rapid Recommendation package. The main infographic presents the recommendations as three paired comparisons, together with an overview of the absolute benefits and harms informing each recommendation, according to the GRADE methodology.

Current practice
Management options for those with patent foramen ovale (PFO) and cryptogenic stroke
Typically, patients with cryptogenic stroke and PFO have three treatment options to reduce the risk of future stroke:
(a) Closure of the PFO with subsequent antiplatelet therapy that may be continued indefinitely or discontinued some months after PFO closure
(b) Antiplatelet therapy alone
(c) Anticoagulant therapy alone.
RAPID RECOMMENDATIONS

Population

People with:

Patent foramen ovale (PFO)

Cryptogenic stroke

No atrial fibrillation
No aortic disease
No left sided heart disease
No cerebrovascular disease

Treatment options:

PFO closure
Anticoagulants
Antiplatelets

Are all options acceptable?

Yes

Anticoagulants contraindicated, unacceptable, or unavailable

Comparison 1
PFO closure or Antiplatelets

Comparison 2
PFO closure or Anticoagulants

Comparison 3
Anticoagulants or Antiplatelets

No atrial fibrillation
No aortic disease
No left sided heart disease
No cerebrovascular disease
RAPID RECOMMENDATIONS

Comparison 1

Comparison of benefits and harms

Within 5 years

<table>
<thead>
<tr>
<th>Event</th>
<th>PFO closure plus antiplatelet therapy</th>
<th>Antiplatelets</th>
<th>Evidence-quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischaemic stroke</td>
<td>12</td>
<td>11</td>
<td>Moderate</td>
</tr>
<tr>
<td>Death</td>
<td>9</td>
<td>3</td>
<td>Moderate</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>7</td>
<td>14</td>
<td>Moderate</td>
</tr>
<tr>
<td>Persistent AF or flutter</td>
<td>23</td>
<td>18</td>
<td>Moderate</td>
</tr>
<tr>
<td>Device-related adverse events</td>
<td>30</td>
<td>36</td>
<td>High</td>
</tr>
</tbody>
</table>

Key practical issues

PFO closure
- Procedure takes under 2 hours
- In hospital stay is usually one day
- Most patients can be resumed within a few days
- Full recovery within a few weeks

Antplatelets
- No key practical issues

Preferences and values

The panel believes that there is probably substantial benefit in stroke reduction after PFO closure, which will be very important to all or almost all patients. This is likely to outweigh important undesirable consequences, like procedure or device-related events and persistent atrial fibrillation

Applicability

The applicability of these findings to patients over 60 and those with traditional cerebrovascular risk factors (e.g. diabetes, hypertension, and hyperlipidemia) is more uncertain. In older patients, fewer cryptogenic strokes are caused by paradoxical emboli, so we expect the benefits of PFO closure would be smaller and the harms greater
### RAPID RECOMMENDATIONS

**Comparison 2**

**PFO closure**

- Percutaneous closure of PFO followed by antiplatelet therapy

**Anticoagulants**

- Anticoagulation therapy

---

**Comparison of benefits and harms**

**Favours PFO closure**

<table>
<thead>
<tr>
<th>Within 5 years</th>
<th>Events per 1000 people</th>
<th>Evidence quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischaemic stroke</td>
<td>13</td>
<td>Moderate</td>
</tr>
<tr>
<td>Death</td>
<td>9</td>
<td>Moderate</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>7</td>
<td>Moderate</td>
</tr>
<tr>
<td>Device-related adverse events</td>
<td>36</td>
<td>High</td>
</tr>
</tbody>
</table>

**Favours anticoagulants**

<table>
<thead>
<tr>
<th>Within 5 years</th>
<th>Events per 1000 people</th>
<th>Evidence quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischaemic stroke</td>
<td>29</td>
<td>Low</td>
</tr>
<tr>
<td>Death</td>
<td>12</td>
<td>Moderate</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>27</td>
<td>Moderate</td>
</tr>
<tr>
<td>Device-related adverse events</td>
<td>36</td>
<td>Low</td>
</tr>
</tbody>
</table>

**Within 1 year**

**Persistent AF or flutter**

<table>
<thead>
<tr>
<th>Events per 1000 people</th>
<th>Evidence quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td>18 fewer</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>7</td>
</tr>
<tr>
<td>Device-related adverse events</td>
<td>36</td>
</tr>
</tbody>
</table>

**Key practical issues**

**PFO closure**

- Procedure takes under 2 hours
- Hospital stay usually one day
- Most activities can be resumed within a few days
- Full recovery within a few weeks

**Anticoagulants**

- Initial frequent testing required to achieve appropriate dose
- Periodic testing required while taking medication

---

**Preferences and values**

The panel felt that many patients would not want the long-term bleeding risk from anticoagulation therapy, which will usually outweigh the probable risk of procedure or device-related events and persistent atrial fibrillation with PFO closure.

---

**Applicability**

The applicability of these findings to patients over 60 and those with traditional cerebrovascular risk factors (e.g., diabetes, hypertension, and hyperlipidaemia) is more uncertain. In older patients, fewer cryptogenic strokes are caused by paradoxical emboli, so we expect the benefits of PFO closure would be smaller and the harms greater.

---

We suggest PFO closure followed by antiplatelet therapy over anticoagulation therapy. Discuss both options with each patient.
Comparison 3

Comparison of benefits and harms

**Anticoagulants**
- **Within 5 years**
  - Ischaemic stroke: 69 events per 1000 people
  - Risk of Bias: No serious concerns
  - Imprecision: Very serious
  - Indirectness: No serious concerns
  - Inconsistency: No serious concerns
  - Publication bias: No serious concerns

**Anticoagulation may decrease ischaemic stroke.**

- **Death**: 13 events per 1000 people
  - Risk of Bias: No serious concerns
  - Imprecision: Very serious
  - Indirectness: No serious concerns
  - Inconsistency: No serious concerns
  - Publication bias: No serious concerns

**Major bleeding**: 26 events per 1000 people
- Risk of Bias: No serious concerns
- Imprecision: No serious concerns
- Indirectness: Serious
- Inconsistency: No serious concerns
- Publication bias: No serious concerns

**Pulmonary embolism**: 1 event per 1000 people
- Risk of Bias: No serious concerns
- Imprecision: No serious concerns
- Indirectness: Serious
- Inconsistency: No serious concerns
- Publication bias: No serious concerns

**Evidence quality**

*Low*  
*Moderate*  
*High*  
*Very high*

We suggest anticoagulation over antiplatelet therapy. Discuss both options with each patient.

**Preferences and values**

The panel felt that the possible decrease in ischaemic stroke with anticoagulants would be more important to most patients than the probable increase in major bleeding. We expect variability in how patients might value these outcomes. Shared decision making may help establish what matters most to each patient.

**Key practical issues**

- **Anticoagulants**
  - Initial frequent testing required to achieve appropriate dose
  - Periodic testing required while taking medication

- **Antiplatelets**
  - No key practical issues

© 2017 BMJ Publishing group Ltd.

Disclaimer: This infographic is not a clinical decision aid. This information is presented for information only. It is not intended to be used as a decision making tool or as a substitute for any expert advice. It should not be used in isolation from all other clinical information. Any patient or public making use of this summary should also consider the wider clinical context. The full publication is available at BMJ’s website and can be found at: [http://www.bmj.com/permissions](http://www.bmj.com/permissions).

See patient decision aids: [MAGIC](http://www.bmj.com/permissions)

See all outcomes: [MAGIC](http://www.bmj.com/permissions)

Find recommendations, evidence summaries and consultation decision aids for use in your practice: [MAGIC app](http://www.bmj.com/permissions)

RAPID RECOMMENDATIONS

Box 1 | Linked resources for this BMJ Rapid Recommendations cluster

  - Summary of the results from the Rapid Recommendation process
  - Review and network meta-analysis of all available randomised trials that assessed PFO closure as adjunct treatment to antiplatelet versus antiplatelet therapy or anticoagulation, and comparing anticoagulants to antiplatelet therapy
- MAGiCapp (https://app.magicapp.org/app#/guideline/2191)
  - Expanded version of the results with multilayered recommendations, evidence summaries, and decision aids for use on all devices

Most current guidelines recommend against routine closure of the PFO in patients with cryptogenic stroke and instead recommend antiplatelets or anticoagulation (the latter if indicated for another reason) (box 2).6,9

Identification of cryptogenic stroke

In about a third of patients in the general population who are diagnosed with an acute ischaemic stroke, investigation finds no clear cause; it is cryptogenic.10 Clinicians reach the diagnosis by ruling out alternative reasons for stroke through prolonged rhythm monitoring to exclude atrial fibrillation; transoesophageal echocardiography or alternative imaging of the aorta and left atrial appendage to rule out aortic atherothrombosis or left atrial clot; and carotid ultrasonography, computed tomography, or magnetic resonance imaging to rule out cerebrovascular disease.

Patients diagnosed with cryptogenic stroke are less likely to have classic risk factors for atheroembolic stroke such as older age, hypertension, hyperlipidaemia, and diabetes.11 They are more likely to have a PFO than patients in the general population.12

Implications of a patent foramen ovale (PFO)

The presence of a PFO does not result in an identifiable increased risk of stroke in the general population.13-15 Many meta-analyses have addressed whether closure of a PFO reduces the long term risk of subsequent stroke,12,16-18 but most have concluded that there is insufficient evidence.6

PFO is a communication between the right and left atrium, typically diagnosed by transthoracic echocardiography with observed flow between the left to right atrium by colour Doppler ultrasonography.19 If the shunt direction reverses, this communication may allow a venous thrombus or right atrial thrombus to travel directly into the arterial circulation and cause a stroke—a phenomenon known as a paradoxical embolism.20-21 This can be characterised with echocardiography (box 3).

The evidence

The linked systematic review reports the relative and the absolute effects of PFO closure followed by antiplatelet therapy versus antiplatelet therapy alone or versus anticoagulation and the effect of anticoagulation versus antiplatelet therapy in patients with cryptogenic stroke and PFO.3 Figure 2 provides an overview of the number and types of patients included, the study funding, and patient involvement.

We conducted a network meta-analysis combining direct evidence (from studies of management in people with cryptogenic stroke comparing at least two of the three options) with indirect evidence (inferring benefits
Box 3 | Details of echocardiographic diagnosis, risk profile, and patent foramen ovale (PFO) procedure planning

- **Which route**—Transesophageal echocardiography has a higher sensitivity for detection of a PFO compared with transthoracic imaging and is recommended in younger adults with unexplained cerebrovascular events.

- **Work-up of cryptogenic stroke**—In addition to detection of PFO, rarer causes of embolic events include an atrial septal defect, cardiac tumours (such as myxoma or papillary fibroelastoma), bacterial or non-bacterial valve vegetations, and atrial thrombi.

- **Detection of PFO**—Microbubbles enter the right atrium, and, if a PFO is present, they pass into the left atrium within a few beats of appearance in the right atrium. Although shunting usually is predominantly left to right, there is some right to left shunting as the relative pressures in the two chambers change during the cardiac cycle and with respiration.
  - Sensitivity of saline contrast for detection of a PFO is increased by asking the patient to perform a Valsalva manoeuvre, which transiently increases right atrial pressure.
  - Estimating the size of a PFO based on the amount of contrast seen in the left atrium may be unreliable.

- **Those with PFO at greater risk**—An atrial septal aneurysm, defined as excessive bulging of an atrial septal fossa ovalis, is often associated with septal fenestrations and may be a marker of increased embolic risk.

- **Ahead of planned PFO closure**—Transesophageal echocardiography is recommended for more detailed visualisation of the atrial septal anatomy when PFO closure is planned.

Extremely imprecise. Only 353 patients were randomised to PFO closure versus anticoagulation, and 405 patients to anticoagulation versus antiplatelet agents, and events were infrequent. Therefore, to obtain more precise estimates, we performed additional analyses based on indirect evidence.

The systematic review also reports indirect evidence, from participants who did not have PFO and cryptogenic stroke, but venous thromboembolism. This evidence was used to inform the effects of anticoagulation versus stroke. Similarly, for the outcome of major bleeding, we performed additional analyses based on indirect evidence comparing anticoagulation with antiplatelet therapy for several non-PFO associated indications.

**Specific groups of PFO patients with cryptogenic stroke**

We hypothesised that studies including more patients with larger shunt sizes, and those that included more patients treated with anticoagulants, would demonstrate larger effects. A separate systematic review reported that PFO closure, compared with any medical therapy, was more effective in patients with moderate or large size shunts. However, the same clinical trials that included more patients with larger shunts also included fewer patients who were prescribed anticoagulants in the medical therapy arm; this confounding makes it impossible to sort out which association (if either) was responsible for the larger effect. Therefore, the shunt size subgroup effect has low credibility (for more details see the linked systematic review).
RAPID RECOMMENDATIONS

HOW THE RECOMMENDATION WAS CREATED

Our international panel included general internists, interventional and non-interventional cardiologists, stroke physicians, epidemiologists, methodologists, statisticians, and people with personal experience of cryptogenic stroke and patent foramen ovale (PFO). They decided on the scope of the recommendation and the outcomes that are most important to patients. The panel identified eight patient-important outcomes needed to inform the recommendation: non-fatal ischaemic stroke, death, major bleeding, pulmonary embolism, serious procedure related or device related adverse events, atrial fibrillation, transient ischaemic attack, and systemic embolism.

A parallel team conducted a systematic review addressing the benefits and harms of three patient-relevant clinical questions framed by the panel: (a) PFO closure with subsequent antiplatelet therapy versus antiplatelet therapy alone, (b) PFO closure with subsequent antiplatelet therapy versus anticoagulation, and (c) anticoagulation versus antiplatelet therapy.1

Because of a lack of evidence in those with PFO, particularly for the anticoagulation option, the panel asked for a summary of the indirect evidence regarding prevention of thrombosis from trials of venous thromboembolism and atrial fibrillation.

We also performed a systematic search for evidence regarding patients’ values and preferences (see appendix 1 on bmj.com).

No panel member had financial conflicts of interest; intellectual and professional conflicts were minimised and managed (for full summary see appendix 2 on bmj.com).

The panel followed the BMJ Rapid Recommendations procedures for creating a trustworthy recommendation,27 including using the GRADE approach to critically appraise the evidence and create recommendations (see appendix 3 on bmj.com).28 The panel considered the balance of benefits, harms, and burdens of the procedure, the quality of the evidence for each outcome, typical and expected variations in patient values and preferences, and acceptability.30 Recommendations can be strong or weak, for or against a course of action.

We were unable to stratify our analyses and recommendations by type or generation of PFO closure device because of the limitations in published data and small subset sample sizes.

Procedure or device related adverse events

Procedure or device related adverse events included vascular complications (1%), conduction abnormalities (1%), device dislocation (0.7%), and device thrombosis (0.5%). Less serious adverse events such as minor bleeding and supraventricular tachycardia were inconsistently reported; the panel judged them as important, however, and took them into account in making recommendations.

Values and preferences

No studies had relevant information on values and preferences. We screened 455 titles and abstracts, and six full text articles. Appendix 1 on bmj.com presents our systematic review of the limited evidence. Three people with experience of living with cryptogenic stroke and PFO provided input regarding the choice of outcomes.

Understanding the recommendations

Absolute benefits and harms

The panel considered PFO closure plus antiplatelets better than antiplatelets alone. This is a strong recommendation because the absolute differences and patient preferences were aligned to place a high value on stroke prevention. Patients are likely to find an absolute reduction of stroke with PFO closure of 8.7% at five years very important. Although 3.6% will experience an adverse event, such events, including 1.8% increase in atrial fibrillation, do not usually result in long term disability and so were considered less important.

The possible small reduction in stroke and decreased bleeding risk with PFO closure versus anticoagulants alone mandated a weak recommendation for PFO closure.

For those patients who need or want to avoid PFO, the panel judged anticoagulation the best alternative, although the evidence regarding stroke reduction was of low certainty. The risk of major bleeding probably increased with anticoagulation. Although direct anticoagulants have not been evaluated in PFO, their advantages in terms of convenience may render them, rather than warfarin, the best option for those who choose anticoagulants.

The main infographic explains the recommendations and provides an overview (GRADE summary of findings) of the absolute benefits (reduction in recurrent ischaemic stroke) and harms of:

- PFO closure followed by antiplatelet therapy versus antiplatelet therapy alone
- PFO closure followed by antiplatelet therapy versus anticoagulants alone
- Anticoagulants versus antiplatelet therapy.

Estimates of baseline risk for effects come from the control arm of the trials, using the median estimate of risk where available.1

The panel agreed that, compared with antiplatelet therapy alone, PFO closure followed by antiplatelet therapy:

- Probably has a large decrease in ischaemic stroke (8.7% absolute risk reduction, moderate quality evidence) over five years
- Has a risk of device or procedure related adverse events (3.6% absolute risk, high quality evidence) at one year
- Probably has an increase in persistent atrial fibrillation or flutter (1.8% absolute risk increase, moderate quality evidence) and transient atrial fibrillation or flutter (1.2% absolute risk increase, moderate quality evidence) at one year
- Probably has little or no difference in death, major bleeding, pulmonary embolism, transient ischaemic attack, or systemic embolism (moderate to high quality evidence) at five years.

The panel agreed that, compared with anticoagulation, PFO closure followed by antiplatelet therapy:

- May result in little or no difference in ischaemic stroke (1.6% absolute risk reduction, low quality evidence) at five years
- Probably decreases major bleeding (2.0% absolute risk reduction, moderate quality evidence) at five years
- Has a risk of device or procedure related adverse events (3.6% absolute risk, high quality evidence) at one year
- Probably has an increase in persistent atrial fibrillation or flutter (1.8% absolute risk increase, moderate quality evidence) and transient atrial fibrillation or flutter (1.2% absolute risk increase, moderate quality evidence) at one year
- Probably has little or no difference in death, pulmonary embolism, transient ischaemic attack, or systemic embolism (moderate quality evidence) at five years.
The panel agreed that anticoagulation versus antiplatelet therapy at five years’ duration:

- May decrease ischaemic stroke (7.1% absolute risk reduction over 5 years, low quality evidence)
- Probably increases major bleeding (1.2% absolute risk increase over 5 years, moderate quality evidence)
- Probably has little or no difference in death, pulmonary embolism, transient ischaemic attack, or systemic embolism (moderate quality evidence).

Values and preferences

**PFO closure followed by antiplatelet therapy versus anticoagulation therapy alone**

Patients for whom anticoagulation is unacceptable or contraindicated should consider PFO closure. Our strong recommendation for PFO closure for such patients reflects the high value they place on avoiding recurrent ischaemic stroke. Patients are likely to find absolute reduction of stroke with PFO closure of 8.7% in five years important. Although 3.6% experience serious device or procedure related adverse events, these do not usually result in long-term disability, and so we considered them less important. Persistent atrial fibrillation after PFO closure procedure might be a concern; however, the main adverse consequence of atrial fibrillation is increased risk of stroke, which was already shown to be substantially lower in patients randomised to PFO closure.

**PFO closure followed by antiplatelet therapy versus anticoagulation**

The major downsides of PFO closure are the 3.6% incidence of complications from the procedure and the probable 1.8% absolute increase in persistent atrial fibrillation. The major downside of anticoagulation is the probable 2.0% absolute increase in bleeding risk over five years. Other issues to consider are the burden and costs of long term anticoagulation. Our weak recommendation for PFO closure reflects (in addition to the low certainty in the estimates of effect) that most serious complications of PFO closure are usually short term, whereas anticoagulation imposes a long-term burden and increased risk of major bleeding. Most fully informed patients would probably accept the transient risk of major adverse events rather than the long-term bleeding risk, but a substantial minority would probably choose anticoagulation.

**Anticoagulation versus antiplatelet therapy**

Patients to whom PFO closure is unacceptable or contraindicated have to choose between anticoagulant or antiplatelet therapy. A typical patient places a high value in a possible absolute reduction of stroke with anticoagulation of 7.1% over five years and would therefore place higher value on the possible benefit of stroke reduction than the probable increased risk of major bleeding. A systematic review\(^2^5\) and a primary study\(^2^6\) of values and preferences on thromboprophylaxis treatment of patients with atrial fibrillation showed that, though preferences were highly variable, most patients value preventing strokes considerably more than they are concerned about increased risk of bleeding. However, there is substantial uncertainty in our estimates for stroke reduction—how this uncertainty would influence decisions is likely to vary substantially. Therefore, we issue a weak recommendation for anticoagulation. Both options need to be discussed with the patient, ideally in a process of shared decision making.

**Practical issues and other considerations**

Figure 3 outlines the key practical issues for patients and clinicians discussing PFO closure and is based on the content expertise of the panel members; practical issues are also accessible, along with the evidence, as decision aids.

### Fig 3] Practical issues about use of percutaneous closure followed by antiplatelet therapy versus anticoagulation therapy alone in patients with patent foramen ovale (PFO) and cryptogenic stroke

The panel agreed that antiplatelet therapy at five years’ duration:

<table>
<thead>
<tr>
<th>PRACTICAL ISSUES</th>
<th>Anticoagulant (warfarin or direct oral anticoagulants (DOAC))</th>
<th>PFO closure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MEDICATION ROUTINE</strong></td>
<td>One dose per day</td>
<td>One dose per day</td>
</tr>
<tr>
<td><strong>TESTS &amp; VISITS</strong></td>
<td>Anticoagulation: frequent testing required to achieve appropriate antiplatelet response</td>
<td>One antiplatelet appointment every 3-6 months</td>
</tr>
<tr>
<td><strong>PROCEDURE &amp; DEVICE</strong></td>
<td>Warfarin: may increase bleeding, may reduce minor bleeding</td>
<td>Most patients can be reassured with a few days, with full recovery within a few weeks</td>
</tr>
<tr>
<td><strong>STROKE &amp; ADAPTATION</strong></td>
<td>May increase bruising</td>
<td>Patients should be given a card to carry, showing the type of device and information to be given in case of a future MRI scan</td>
</tr>
<tr>
<td><strong>FOOD &amp; DRINK</strong></td>
<td>May increase risk of peptic ulcer</td>
<td>Patients are proaged to continue taking medication while avoiding certain foods</td>
</tr>
<tr>
<td><strong>EXERCISE &amp; ACTIVITIES</strong></td>
<td>May increase risk of bleeding (especially if antiplatelet therapy)</td>
<td>Involves low dose radiation exposure to certain staff</td>
</tr>
<tr>
<td><strong>WORK &amp; EDUCATION</strong></td>
<td>May make light activities with high ischaemic load more uncomfortable</td>
<td>Increased risk of minor discomfort or side effects of other procedures</td>
</tr>
<tr>
<td><strong>TRAVEL &amp; DRIVING</strong></td>
<td>May reduce light activities with high ischaemic load</td>
<td>Can reduce the risk of major adverse events during the first days to weeks from the procedure</td>
</tr>
</tbody>
</table>

---

**Notes:**

- DOAC: Direct oral anticoagulants (warfarin or direct oral anticoagulants (DOAC))
- PFO: Patent foramen ovale
- DOAC: Direct oral anticoagulants
- PFO closure: Percutaneous closure
- Warfarin: Oral anticoagulants

---

**References:**

1. Review of evidence on thromboprophylaxis treatment of patients with atrial fibrillation.
2. Primary study of values and preferences on thromboprophylaxis treatment of patients with atrial fibrillation.
3. Systematic review of values and preferences on thromboprophylaxis treatment of patients with atrial fibrillation.
4. BMJ: first published as 10.1136/bmj.k2515 on 25 July 2018. Downloaded from http://www.bmj.com on 31 December 2023 by guest. Protected by copyright.
RAPID RECOMMENDATIONS

EDUCATION INTO PRACTICE

- Does this article offer new ways to approach advising patients with cryptogenic ischaemic stroke presumed to be related to a patent foramen ovale (PFO)?
- How might you better respect differences in patients’ preferences, particularly their perspective regarding the bleeding risk associated with long term anticoagulation or their feelings about undergoing an invasive procedure?
- What information could you share with your patients to help them reach a decision?
- How might you share this information with colleagues to learn together?

HOW PATIENTS WERE INVOLVED IN THE CREATION OF THIS ARTICLE

The panel included three people with personal experience of cryptogenic stroke and patent foramen ovale (PFO). These panel members identified important outcomes, and led the discussion on values and preferences. The patients agreed that, in general, small reductions in risk of ischaemic stroke are more important to them than small increases in risk of atrial fibrillation or of device or procedure related adverse events. We expect these values to be shared by most patients for ischaemic stroke. The patients participated as full panel members in the teleconferences and email discussions and met all authorship criteria. They had equal input as any other author on the recommendation.

New evidence which has emerged after initial publication

- Which device for PFO closure is:
- What is the longevity of the PFO closure device and ongoing need for monitoring of device performance?

Updates to this article

The table shows evidence which has emerged since the publication of this article. As new evidence is published, a group will assess the new evidence and make a judgment on to what extent it is expected to alter the recommendation.

Costs and resources

The panel focused on the patient’s perspective rather than that of society when formulating the recommendation. Because PFO closure is associated with higher costs related to the procedure, implementation of this recommendation is likely to have an important impact on the costs for health funders in the short term. Over the long term, however, PFO closure may reduce costs as a result of reduced stroke rates and reduction in associated costs.2 Addressing this issue formally would require a cost effectiveness analysis.

Uncertainties to be addressed in future research

The key remaining research question is the relative merit of PFO closure versus anticoagulation alone. It may also be appropriate to conduct further trials of PFO closure versus antplatelet agents alone in those with small PFOs. Longer trials are also needed to address the longevity of the PFO closure device and ongoing need for monitoring of device performance.

Key research questions to inform decision makers and future guidelines include:
- What are the benefits and harms of PFO closure versus anticoagulants (including direct oral anticoagulants) in patients with PFO and cryptogenic stroke?
- What patient groups are more likely to benefit from PFO closure versus medical therapy? (That is, explore whether the effect of PFO closure versus medical therapy varies with shunt size, presence of atrial septal aneurysm, and age.)

<table>
<thead>
<tr>
<th>Date</th>
<th>New evidence</th>
<th>Citation</th>
<th>Findings</th>
<th>Implications for recommendation(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Are there currently no updates to the article.</td>
</tr>
</tbody>
</table>

8. Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events (Interventional procedures guideline (IPG-2)): NICE, 2013: www.nice.org.uk/guidance/ipg2/about/chapter/1-recommendations.
RAPID RECOMMENDATIONS


Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/rights-licensing/permissions

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

1 Department of guideline development and research, Dutch College of General Practitioners, Utrecht, The Netherlands

2 McMaster University, Hamilton, Canada

3 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada L8S 4L8

4 Department of Medicine, University of Toronto, Toronto, Ontario, Canada

5 Norwegian Institute of Public Health, Oslo, Norway

6 Department of Medicine, Imland Hospital Trust - division Gjøvik, Norway

7 University of Washington, Seattle, District of Columbia, USA

8 Division of Neurology, Department of Medicine, Queen's University, Kingston, Ontario, Canada

9 University of California Davis, Sacramento, CA, USA

10 All India Institute of Medical Sciences, New Delhi, India

11 University Medical Center Groningen, Groningen, The Netherlands

12 Departments of Anesthesi & Perioperative Medicine, and Epidemiology & Biostatistics, University of California, Los Angeles, USA

13 Division General Internal Medicine, University Hospitals of Geneva, CH-1211, Geneva, Switzerland

14 NUI Galway, Galway, Ireland

15 Oslo University Hospital, Oslo, Norway

16 Las Vegas, Nevada, USA

17 Boulder, Colorado, USA

18 Wevelift, Herfordshire, UK

19 Division General Internal Medicine & Division of Clinical Epidemiology, University Hospitals of Geneva, CH-1211, Geneva, Switzerland